Literature DB >> 33646347

Approaching precision medicine by tailoring the microbiota.

Gaeun Ryu1, Hyojin Kim1, Ara Koh2,3.   

Abstract

Accumulating evidence has revealed the link between the microbiota and various human diseases. Advances in high-throughput sequencing technologies have identified some consistent disease-associated microbial features, leading to the emerging concept of microbiome-based therapeutics. However, it is also becoming clear that there are considerable variations in the microbiota among patients with the same disease. Variations in the microbial composition and function contribute to substantial differences in metabolic status of the host via production of a myriad of biochemically and functionally different microbial metabolites. Indeed, compelling evidence indicates that individuality of the microbiome may result in individualized responses to microbiome-based therapeutics and other interventions. Mechanistic understanding of the role of the microbiota in diseases and drug metabolism would help us to identify causal relationships and thus guide the development of microbiome-based precision or personalized medicine. In this review, we provide an overview of current efforts to use microbiome-based interventions for the treatment of diseases such as cancer, neurological disorders, and diabetes to approach precision medicine.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Mesh:

Year:  2021        PMID: 33646347     DOI: 10.1007/s00335-021-09859-3

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  147 in total

1.  Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis.

Authors:  Cindy Baldwin; Mathieu Millette; Daniel Oth; Marcia T Ruiz; François-Marie Luquet; Monique Lacroix
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  γ-Aminobutyric acid production by culturable bacteria from the human intestine.

Authors:  E Barrett; R P Ross; P W O'Toole; G F Fitzgerald; C Stanton
Journal:  J Appl Microbiol       Date:  2012-06-15       Impact factor: 3.772

3.  A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis.

Authors:  Shaheen Alanee; Ahmed El-Zawahry; Danuta Dynda; Ali Dabaja; Kevin McVary; Mallory Karr; Andrea Braundmeier-Fleming
Journal:  Prostate       Date:  2018-08-16       Impact factor: 4.104

4.  The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans.

Authors:  Pénélope A Andreux; William Blanco-Bose; Dongryeol Ryu; Frédéric Burdet; Mark Ibberson; Patrick Aebischer; Johan Auwerx; Anurag Singh; Chris Rinsch
Journal:  Nat Metab       Date:  2019-06-14

5.  Increased serum deoxycholic acid levels in men with colorectal adenomas.

Authors:  E Bayerdörffer; G A Mannes; W O Richter; T Ochsenkühn; B Wiebecke; W Köpcke; G Paumgartner
Journal:  Gastroenterology       Date:  1993-01       Impact factor: 22.682

6.  Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation.

Authors:  Dionysios A Antonopoulos; Susan M Huse; Hilary G Morrison; Thomas M Schmidt; Mitchell L Sogin; Vincent B Young
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

7.  Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients.

Authors:  J R Bedarf; F Hildebrand; L P Coelho; S Sunagawa; M Bahram; F Goeser; P Bork; U Wüllner
Journal:  Genome Med       Date:  2017-04-28       Impact factor: 11.117

8.  Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice.

Authors:  Tulika Arora; Udo Wegmann; Anup Bobhate; Ying Shiuan Lee; Thomas U Greiner; Daniel J Drucker; Arjan Narbad; Fredrik Bäckhed
Journal:  Mol Metab       Date:  2016-06-22       Impact factor: 7.422

9.  Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy.

Authors:  Aadra P Bhatt; Samuel J Pellock; Kristen A Biernat; William G Walton; Bret D Wallace; Benjamin C Creekmore; Marine M Letertre; Jonathan R Swann; Ian D Wilson; Jose R Roques; David B Darr; Sean T Bailey; Stephanie A Montgomery; Jeffrey M Roach; M Andrea Azcarate-Peril; R Balfour Sartor; Raad Z Gharaibeh; Scott J Bultman; Matthew R Redinbo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-13       Impact factor: 11.205

10.  Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions.

Authors:  Federico Baldini; Johannes Hertel; Estelle Sandt; Cyrille C Thinnes; Lorieza Neuberger-Castillo; Lukas Pavelka; Fay Betsou; Rejko Krüger; Ines Thiele
Journal:  BMC Biol       Date:  2020-06-09       Impact factor: 7.431

View more
  1 in total

Review 1.  The Future of Synbiotics: Rational Formulation and Design.

Authors:  David F Gomez Quintero; Car Reen Kok; Robert Hutkins
Journal:  Front Microbiol       Date:  2022-07-22       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.